Clinical Trials, Data, Document and THC

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is IGC’s proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimer’s disease. The degree of the decrease varied by cohort.

Clinical Trials

Clinical Trials Data Patients THC

CBD Science Update

Project CBD

AUGUST 6, 2019

Over 200 scientists from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpiblished data. None of the participants had been using any cannabinoid-based products prior to this study.

CBD

CBD Blood Pressure Research and Development Cannabinoids

CBD Science Update

Project CBD

AUGUST 6, 2019

Just over 500 participants from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpublished data. None of the participants had been using any cannabinoid-based products prior to this study.

CBD

CBD Blood Pressure Research and Development Cannabinoids

Here’s what you need to know about cannabis research

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.

Research and Development

Research and Development Data THC Clinical Trials

Recent Study Suggests MMJ Cards Increase the Risk of CUD—But Is There More to It?

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size. Does the Data Justify the Conclusions? Investigating the Impact of MMJ Cards. Various Limitations.

Research and Development

Research and Development Clinical Trials Consumption Patients

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

DECEMBER 7, 2021

However, despite the increased use of MCs in children, there is limited data regarding their safety and efficacy in this population for those different indications 11. A systematic review published in 2017 aimed to identify available data about the therapeutic effect of cannabinoids treatment in children and adolescents.

Safety

Safety Cannabinoids Events Data

Researchers Call for Caution: Some CBD Pet Products Have Absolutely No CBD

The Joint Blog

JANUARY 12, 2020

“The growth is more rapid than I’ve seen for any product in 20 years in this business,” said Bill Bookout, president of the National Animal Supplement Council, an industry group whose member companies agree to testing and data-gathering requirements. Still, scientific documentation of CBD’s safety and efficacy is nearly nonexistent.

Pets

Pets CBD Clinical Trials Research and Development

What Marijuana Patients with Heart Problems Need to Know

CannaMD

MARCH 8, 2020

Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease.

Patients

Patients Marijuana Research and Development Clinical Trials

Cannabis Standards Rely on Transparency, Compliance and Collaboration

Cannabis Law Report

MARCH 29, 2020

According to Vividata’s National Cannabis Consumer Study , 70% of consumers are not sure they know the difference between THC and CBD. This “zero recall” standard, the team said, was attributed to the fact that their cannabis product standards with regard to food safety and health was high and involved documentation of over 100 pages. .

Compliance

Compliance Compliance Supply Chain Research and Development

Cannabis as a cancer cure: what is the research and where is it going?

The Cannigma

FEBRUARY 1, 2023

To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. When THC binds to the CB1 receptor, this is what produces the well-known high associated with cannabis. Importantly, research is underway to determine the antitumor effects of cannabinoids!

Clinical Trials

Clinical Trials Research and Development Therapy Cannabinoids

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Its adaptation in Western countries like the UK has been well documented, where it was used in the nineteenth and early twentieth centuries as an analgesic, anti-spasmodic, appetite stimulant, and topical anaesthetic (Aldrich 1997 ). Data collection.

Research and Development

Research and Development Medicine Access Media

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

OCTOBER 29, 2019

The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety

Safety CBD Clinical Trials Oil

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Extraction

Extraction Pharmaceutical CBD Epilepsy

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. A THC version is expected to follow, and potentially one with psychedelic mushrooms. Rick Doblin, Ph.D, in/rickdoblin/ [link].

Research and Development

Research and Development Medicine Treatment Pharmaceutical

Buzzes & Bummers: 2018 Was a Wild Ride in the World of Cannabis

SpeedWeed

DECEMBER 28, 2018

As first reported by Leafly, Altria has “over the past five years quietly patented dozens of devices that could be used to consume marijuana, a review of public documents at the US Patent and Trademark Office shows.” Which Cannabis Strains Are Highest in CBD, According to Lab Data? RELATED STORY.

Pharmaceutical

Pharmaceutical Research and Development Legalization CBD

Why Dr. Sue Sisley Sued the DEA for Stonewalling Cannabis Research

NORML

SEPTEMBER 20, 2019

Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials. Dr. Sue Sisley: Basically, it comes in these generic batches of either high-THC, high-CBD, or placebo cannabis. Photo courtesy MAPS.

DEA

DEA Research and Development Clinical Trials Patients

Dentons’ Cannabis Group Latest Weekly Update – June 2019 #4

Cannabis Law Report

JUNE 30, 2019

Lou Correa (D-CA) that would require the VA to conduct clinical trials on the therapeutic potential of cannabis in the treatment of such service-related conditions as post-traumatic stress disorder and chronic pain. Congress has asked vaporizer company JUUL for documents on any partnerships it may have with cannabis companies.

Chronic Pain

Chronic Pain Legislation Treatment Programs

Medical Cannabis Brief

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

CBD Science Update

Trending Sources

CBD Science Update

Here’s what you need to know about cannabis research

Recent Study Suggests MMJ Cards Increase the Risk of CUD—But Is There More to It?

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Researchers Call for Caution: Some CBD Pet Products Have Absolutely No CBD

What Marijuana Patients with Heart Problems Need to Know

Cannabis Standards Rely on Transparency, Compliance and Collaboration

Cannabis as a cancer cure: what is the research and where is it going?

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

ElleVet Sciences Publishes Safety Study On CBD For Animals

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Buzzes & Bummers: 2018 Was a Wild Ride in the World of Cannabis

Why Dr. Sue Sisley Sued the DEA for Stonewalling Cannabis Research

Dentons’ Cannabis Group Latest Weekly Update – June 2019 #4

Stay Connected